Literature DB >> 20656128

Chemokines and glioma: invasion and more.

Giuseppe Sciumè1, Angela Santoni, Giovanni Bernardini.   

Abstract

Increasing pieces of evidence indicate that the chemokine system influences several aspects of brain physiology and pathology. A deregulated chemokine expression pattern is observed during neurological diseases, including multiple sclerosis and brain tumor. Gliomas are the most common primary tumors affecting human central nervous system (CNS). Chemokines expressed by stromal cells or endogenously produced by glioma cells may influence tumor cell migration, invasion, proliferation, angiogenesis and immune cell infiltration in the tumor mass. Herein we focus on chemokines and chemokine receptors expressed by glioma cells and their role in the regulation of glioma cell functional behaviour, including its ability to attract immune cells. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656128     DOI: 10.1016/j.jneuroim.2010.05.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  37 in total

Review 1.  Role of AHR and HIF-1α in Glioblastoma Metabolism.

Authors:  Galina Gabriely; Michael A Wheeler; Maisa C Takenaka; Francisco J Quintana
Journal:  Trends Endocrinol Metab       Date:  2017-03-16       Impact factor: 12.015

2.  CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5.

Authors:  Kien Pham; Defang Luo; Che Liu; Jeffrey K Harrison
Journal:  J Neuroimmunol       Date:  2012-03-16       Impact factor: 3.478

3.  Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas.

Authors:  Xiao-Bing Wang; Xiao-Ying Tian; Yang Li; Bin Li; Zhi Li
Journal:  J Neurooncol       Date:  2011-07-03       Impact factor: 4.130

Review 4.  Role of AHR in the control of GBM-associated myeloid cells.

Authors:  Galina Gabriely; Francisco J Quintana
Journal:  Semin Cancer Biol       Date:  2019-05-23       Impact factor: 15.707

Review 5.  CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

Authors:  Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

6.  Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.

Authors:  Monika A Davare; Sangeet Lal; Jennifer L Peckham; Suresh I Prajapati; Sakir H Gultekin; Brian P Rubin; Charles Keller
Journal:  Biochem Biophys Res Commun       Date:  2014-06-10       Impact factor: 3.575

7.  Treating brain tumors with PDE4 inhibitors.

Authors:  Rajarshi Sengupta; Tao Sun; Nicole M Warrington; Joshua B Rubin
Journal:  Trends Pharmacol Sci       Date:  2011-03-28       Impact factor: 14.819

8.  Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.

Authors:  Liu Yang; Mei Liu; Chuanzong Deng; Zhikai Gu; Yilu Gao
Journal:  Tumour Biol       Date:  2012-04-29

9.  Effects of Rab27a on proliferation, invasion, and anti-apoptosis in human glioma cell.

Authors:  Xiuwei Wu; Anla Hu; Mingjun Zhang; Zhendong Chen
Journal:  Tumour Biol       Date:  2013-04-04

Review 10.  Identifying new small molecule anti-invasive compounds for glioma treatment.

Authors:  Jennifer Munson; Michael Bonner; Levi Fried; Jonathan Hofmekler; Jack Arbiser; Ravi Bellamkonda
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.